Lymphoma News

Ambient Benzene Exposure and Risk of Hematologic Malignancies

Ambient Benzene Exposure and Risk of Hematologic Malignancies

Researchers examined low-level estimates of ambient benzene to investigate whether it was associated with increased cancer incidence across a nationwide cohort.

Ibrutinib Plus Nivolumab in 4 Cohorts of Patients With R/R NHL or CLL

Ibrutinib Plus Nivolumab in 4 Cohorts of Patients With R/R NHL or CLL

According to results of an exploratory study, patients with Richter transformation may benefit from treatment with ibrutinib plus nivolumab.

Assessment of Treatment Intensity as a Predictor of Benefit in DLBCL

Assessment of Treatment Intensity as a Predictor of Benefit in DLBCL

Patients with newly-diagnosed DLBCL receiving R-CHOP at or near full-dose intensity have improved overall survival, according to study authors.

A 5-Feature Radiomics Model to Predict Refractory Disease in Early-Stage Hodgkin Lymphoma

A 5-Feature Radiomics Model to Predict Refractory Disease in Early-Stage Hodgkin Lymphoma

A study of the use of precision medicine-based "radiomic" features to evaluate risk of refractory disease in early-stage Hodgkin lymphoma showed promising results.

Low-Dose Lenalidomide Maintenance in Older Patients With PCNSL

Low-Dose Lenalidomide Maintenance in Older Patients With PCNSL

Given the high likelihood of comorbidities and poor performance status in older patients with PCNSL, alternative treatment approaches are needed for this population of patients.

FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma

FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma

The US FDA provided updated information to women with breast implants and their health care providers on the risk of developing a specific type of lymphoma.

NICE Recommends Use of Tisagenlecleucel for Adults With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NICE Recommends Use of Tisagenlecleucel for Adults With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Adults in the UK with R/R DLBCL and their health care providers now have the option of considering treatment with tisagenlecleucel, a CAR-T cell therapy.

Expression Levels of NOTCH3 Minus Exon 16 as a Potential Prognostic Biomarker in Diffuse Large B-Cell Lymphoma

Expression Levels of NOTCH3 Minus Exon 16 as a Potential Prognostic Biomarker in Diffuse Large B-Cell Lymphoma

Spliced events in NOTCH genes may facilitate risk stratification for patients with certain subtypes of DLBCL.

FDA Grants IND Clearance for ALLO-501, an Allogeneic CAR-T Candidate

FDA Grants IND Clearance for ALLO-501, an Allogeneic CAR-T Candidate

Initiation of a phase 1 clinical trial of ALLO-501, an allogeneic CAR-T candidate, in patients with NHL is planned for early 2019.

EBV-Positive Lymphomas Associated With Somatic Alterations in Genes Encoding for PD-L1 and PD-L2

EBV-Positive Lymphomas Associated With Somatic Alterations in Genes Encoding for PD-L1 and PD-L2

Detection of specific mutations in genes encoding for PD-L1 and PD-L2 may help predict which patients with lymphoma will benefit from immune checkpoint inhibitor therapy.

Leading Cause of Death in Follicular Lymphoma Remains Disease Itself

Leading Cause of Death in Follicular Lymphoma Remains Disease Itself

The leading cause of death for patients with follicular lymphoma was the disease itself, despite gains in survival due to rituximab treatment.

Long-Term Outcomes of Axicabtagene Ciloleucel: ZUMA-1

Long-Term Outcomes of Axicabtagene Ciloleucel: ZUMA-1

In the ZUMA-1 trial, axicabtagene ciloleucel showed durable responses and no new safety concerns in patients with relapsed or refractory large B-cell lymphoma.

Primary End Point Not Met in Trial Testing Nivolumab Monotherapy for DLBCL

Primary End Point Not Met in Trial Testing Nivolumab Monotherapy for DLBCL

Nivolumab monotherapy for R/R DLBCL failed to confer improved objective response rates, but did produce durable responses in 3 individuals.

Chemoimmunotherapy Regimen Confers Benefit in Double Expressor DLBCL

Chemoimmunotherapy Regimen Confers Benefit in Double Expressor DLBCL

Patients younger than 65 with double expressor diffuse large B-cell lymphoma had better outcomes with dose-adjusted EPOCH plus rituximab than R-CHOP.

Single-Cell Examination Can Provide Insights into Tumor Microenvironment

Single-Cell Examination Can Provide Insights into Tumor Microenvironment

Cellular examination of follicular lymphoma reveals malignant B-cell types, coexpression of T-cell immune checkpoints.

CHIP Associated with Poorer Outcomes in Lymphoma

CHIP Associated with Poorer Outcomes in Lymphoma

Clonal hematopoiesis of indeterminate potential is associated with shorter overall and event-free survival after autologous transplant in lymphoma.

Front-Line Bendamustine Combination Linked With Stem Cell Mobilization Failure in MCL

Front-Line Bendamustine Combination Linked With Stem Cell Mobilization Failure in MCL

Bendamustine-rituximab combination increased risk for day 1 stem cell mobilization failure

Rituximab Biosimilar CT-P10 Equivalent as Monotherapy for Follicular Lymphoma

Rituximab Biosimilar CT-P10 Equivalent as Monotherapy for Follicular Lymphoma

US FDA recently approved rituximab biosimilar as monotherapy and in combination with chemotherapy.

Long-Term Data Show Low Risk of Second Primary Malignancy, Transformation in WM

Long-Term Data Show Low Risk of Second Primary Malignancy, Transformation in WM

Study shows risk of second primary malignancy or transformation to lymphoma is low.

Yescarta in the Real-World Setting: How Did the Results Compare With ZUMA-1 Outcomes?

Yescarta in the Real-World Setting: How Did the Results Compare With ZUMA-1 Outcomes?

Inferior patient outcomes from treatment with axi-cel were linked to poor performance status and increased tumor bulk in patients.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs